Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China flag China · Delayed Price · Currency is CNY
10.79
-0.12 (-1.10%)
Sep 16, 2026, 3:04 PM CST

SHE:002727 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
16,26816,73617,46216,87717,12414,275
Other Revenue
620.55599.91538.72503.73307.42312.21
16,88917,33618,00017,38017,43214,587
Revenue Growth
-4.09%-3.69%3.57%-0.29%19.50%15.26%
Cost of Revenue
11,45511,82912,42811,79811,4869,320
Gross Profit
5,4345,5075,5735,5825,9465,267
Selling, General & Admin
4,8784,9415,1664,6634,5124,087
Research & Development
5.6910.599.7110.28.745.39
Other Operating Expenses
-1.73-11.167.6732.6217.17-13.93
Operating Expenses
4,9164,9785,1904,7394,6284,082
Operating Income
517.54528.4383.26843.931,3181,185
Interest Expense
-121.89-133.22-146.04-135.34-93.72-136.22
Interest & Investment Income
17.421.0247.0486.487.4953.52
Currency Exchange Gain (Loss)
----0.23-0.09
Other Non Operating Income (Expenses)
-1.83-4.37-76.25-93.761.48-4.53
EBT Excluding Unusual Items
411.23411.83208701.321,2331,098
Impairment of Goodwill
-21.44-21.44-26.77-11.65-12.29-10.97
Gain (Loss) on Sale of Investments
-5.24-7.1-3.43-8.36-5.72-5.77
Gain (Loss) on Sale of Assets
10.58.793.181.12-13.83-13.41
Asset Writedown
-3.33-3.29-2.17-2.93-13.85-2.71
Other Unusual Items
39.7517.828.523.0747.4831.29
Pretax Income
431.47406.59207.31702.561,2351,097
Income Tax Expense
156.65134.8997.02142.15222179.32
Earnings From Continuing Operations
274.82271.71110.29560.411,013917.21
Minority Interest in Earnings
-4.19-8.273.85-10.97-2.984.38
Net Income
270.63263.43114.14549.441,010921.58
Net Income to Common
270.63263.43114.14549.441,010921.58
Net Income Growth
230.50%130.80%-79.23%-45.60%9.59%16.66%
Shares Outstanding (Basic)
571576592597593590
Shares Outstanding (Diluted)
571576592597595592
Shares Change
-2.82%-2.70%-0.76%0.27%0.50%3.32%
EPS (Basic)
0.470.460.190.921.701.56
EPS (Diluted)
0.470.460.190.921.701.56
EPS Growth
240.11%137.21%-79.07%-45.75%9.05%12.91%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,6861,3551,4661,8622,1481,400
Free Cash Flow Per Share
2.962.352.483.123.612.36
Dividend Per Share
0.4000.4000.3000.4000.4000.300
Dividend Growth
-20.00%33.33%-25.00%0%33.33%0%
Gross Margin
32.17%31.77%30.96%32.12%34.11%36.11%
Operating Margin
3.06%3.05%2.13%4.86%7.56%8.13%
Profit Margin
1.60%1.52%0.63%3.16%5.79%6.32%
Free Cash Flow Margin
9.99%7.82%8.14%10.71%12.32%9.60%
EBITDA
616.22636.54503.29968.591,4321,283
EBITDA Margin
3.65%3.67%2.80%5.57%8.22%8.80%
D&A For EBITDA
98.68108.14120.03124.66114.4698.08
EBIT
517.54528.4383.26843.931,3181,185
EBIT Margin
3.06%3.05%2.13%4.86%7.56%8.13%
Effective Tax Rate
36.31%33.17%46.80%20.23%17.98%16.35%
Revenue as Reported
16,88917,33618,00017,38017,43214,587
Advertising Expenses
-50.1362.949.5549.2842.16